Enjoy complimentary customisation on priority with our Enterprise License!
The selective serotonin reuptake inhibitors (SSRIs) market size has the potential to grow by USD 809.73 million during 2021-2025, and the market’s growth momentum will accelerate at a CAGR of 4%.
This report provides a detailed analysis of the market by application (depression, anxiety and panic disorder, and other mental conditions), geography (North America, Europe, Asia, and ROW), and key vendors.
Browse TOC and LoE with selected illustrations and example pages of Selective Serotonin Reuptake Inhibitors (SSRIs) Market
The report analyzes the market’s competitive landscape and offers information on several market vendors, including:
The selective serotonin reuptake inhibitors (SSRIs) market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market. Click here to uncover other successful business strategies deployed by the vendors.
The market players also significantly leverage external market drivers such as rising prevalence of mental illnesses to achieve growth opportunities. However, factors such as side effects of antidepressants will challenge the growth of the market participants. To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
Download a free sample of the selective serotonin reuptake inhibitors (SSRIs) market forecast report for insights on complete key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
This selective serotonin reuptake inhibitors (SSRIs) market analysis report also provides detailed information on the upcoming trends and challenges that will influence market growth. This will help companies create strategies to make the most of future growth opportunities.
|
|
Grab your Free Sample now to unlock further information on other key market drivers
For more insights on the market share of various regions Request for a FREE sample now!
41% of the market’s growth will originate from North America during the forecast period. The US is one of the key markets for selective serotonin reuptake inhibitors (SSRIs) in North America. Market growth in this region will be slower than the growth of the market in Asia.
The presence of many pharmaceutical companies that offer both branded and generic SSRIs drugs is one of the prime factors that will facilitate the selective serotonin reuptake inhibitors (SSRIs) market growth in North America over the forecast period. To garner further competitive intelligence and regional opportunities in store for vendors, view our sample report.
Request for a FREE sample and Get more information on the market contribution of various segments
The incidence of depression has been increasing across the globe. Serotonin levels have a direct correlation with depression. A drop in the serotonin level indicates depression. Therefore, pharmaceutical companies have formulated SSRIs drugs that can inhibit 5-hydroxytryptamine (5-HT) reuptake transporters to increase the serotonin concentration at the synaptic cleft. Also, SSRIs drugs are better absorbed in gastrointestinal tracts compared with other antidepressants. The growth of the market segment is expected to be significant during the forecast period.
Fetch actionable market insights on post COVID-19 impact on each segment. This report provides an accurate prediction of the contribution of all the segments to the growth of the selective serotonin reuptake inhibitors (SSRIs) market size.
We can help! Our analysts can customize this report to meet your requirements. Get in touch
|
Selective Serotonin Reuptake Inhibitors (SSRIs) Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
120 |
|
Base year |
2020 |
|
Forecast period |
2021-2025 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 4% |
|
Market growth 2021-2025 |
$ 809.73 million |
|
Market structure |
Fragmented |
|
YoY growth (%) |
3.15 |
|
Regional analysis |
North America, Europe, Asia, and ROW |
|
Performing market contribution |
North America at 41% |
|
Key consumer countries |
US, Germany, China, UK, and France |
|
Competitive landscape |
Leading companies, competitive strategies, consumer engagement scope |
|
Companies profiled |
AbbVie Inc., Apotex Inc., Aurobindo Pharma Ltd., Cipla Inc., Eli Lilly and Co., GlaxoSmithKline Plc, H. Lundbeck AS, Lupin Ltd., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd. |
|
Market Dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for forecast period, |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Executive Summary
Market Landscape
Market Sizing
Five Forces Analysis
Market Segmentation by Application
Customer landscape
Geographic Landscape
Vendor Landscape
Vendor Analysis
Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.